{"id":7237,"date":"2022-06-23T14:34:18","date_gmt":"2022-06-23T12:34:18","guid":{"rendered":"http:\/\/www.seventure.fr\/?p=7237"},"modified":"2022-06-23T14:35:11","modified_gmt":"2022-06-23T12:35:11","slug":"galecto-announces-first-patient-enrolled-in-phase-2-trial-of-gb1211-in-combination-with-atezolizumab-for-first-line-treatment-of-nsclc","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/galecto-announces-first-patient-enrolled-in-phase-2-trial-of-gb1211-in-combination-with-atezolizumab-for-first-line-treatment-of-nsclc\/","title":{"rendered":"Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,104],"tags":[],"class_list":["post-7237","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-medtech-diagnosis"],"acf":[],"yoast_head":"\n